Clinical trial into puberty blockers paused after ‘new concerns’

Baroness Hilary Cass, who led that review, has previously said her report “uncovered a very weak evidence base” for the benefits of puberty blockers for children and young people with gender dysphoria, but that “given that there are clinicians, children and families who believe passionately in the beneficial effects, a trial was the only way forward to make sense of this”.